A critical overview of targeted therapies for glioblastoma
KK Jain - Frontiers in oncology, 2018 - frontiersin.org
Over the past century, treatment of malignant tumors of the brain has remained a challenge.
Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents …
Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents …
[HTML][HTML] DNA repair mechanisms and their clinical impact in glioblastoma
H Erasimus, M Gobin, S Niclou, E Van Dyck - Mutation Research/Reviews …, 2016 - Elsevier
Despite surgical resection and genotoxic treatment with ionizing radiation and the DNA
alkylating agent temozolomide, glioblastoma remains one of the most lethal cancers, due in …
alkylating agent temozolomide, glioblastoma remains one of the most lethal cancers, due in …
In vivo HSC prime editing rescues sickle cell disease in a mouse model
Sickle cell disease (SCD) is a monogenic disease caused by a nucleotide mutation in the β-
globin gene. Current gene therapy studies are mainly focused on lentiviral vector–mediated …
globin gene. Current gene therapy studies are mainly focused on lentiviral vector–mediated …
Gene therapy: progress and predictions
M Collins, A Thrasher - … of the Royal Society B: Biological …, 2015 - royalsocietypublishing.org
The first clinical gene delivery, which involved insertion of a marker gene into lymphocytes
from cancer patients, was published 25 years ago. In this review, we describe progress …
from cancer patients, was published 25 years ago. In this review, we describe progress …
[HTML][HTML] In vivo HSC gene therapy using a bi-modular HDAd5/35++ vector cures sickle cell disease in a mouse model
We have recently reported that, after in vivo hematopoietic stem cell/progenitor (HSPC)
transduction with HDAd5/35++ vectors, SB100x transposase-mediated γ-globin gene …
transduction with HDAd5/35++ vectors, SB100x transposase-mediated γ-globin gene …
[HTML][HTML] Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology
J Yang, Z Shi, R Liu, Y Wu, X Zhang - Theranostics, 2020 - ncbi.nlm.nih.gov
Glioblastoma multiforme (GBM) is a highly aggressive and devastating brain tumor
characterized by poor prognosis and high rates of recurrence. Numerous therapeutic …
characterized by poor prognosis and high rates of recurrence. Numerous therapeutic …
Nanoparticles‐mediated combination therapies for cancer treatment
Cancer is a dynamic disease characterized by its heterogeneous nature. This heterogeneity
results in critical problems that interfere with the eradication of cancer tumors such as …
results in critical problems that interfere with the eradication of cancer tumors such as …
MiR-7-5p suppresses stemness and enhances temozolomide sensitivity of drug-resistant glioblastoma cells by targeting Yin Yang 1
B Jia, W Liu, J Gu, J Wang, W Lv, W Zhang… - Experimental cell …, 2019 - Elsevier
Glioblastoma multiforme (GBM) is the most malignant tumor of the central nervous system,
and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM …
and chemoresistance blunts the effect of temozolomide (TMZ) in the treatment of GBM …
Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells
Pluripotent stem cells (PSCs) represent an alternative hematopoietic stem cell (HSC) source
for treating hematopoietic disease. The limited engraftment of human PSC–derived (hPSC …
for treating hematopoietic disease. The limited engraftment of human PSC–derived (hPSC …
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory
J Wu, DJ Waxman - Oncoimmunology, 2015 - Taylor & Francis
Cancer chemotherapy using cytotoxic drugs can induce immunogenic tumor cell death;
however, dosing regimens and schedules that enable single-agent chemotherapy to induce …
however, dosing regimens and schedules that enable single-agent chemotherapy to induce …